Previous 10 | Next 10 |
MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the United Kingdom’s...
The recent stock rally has made some crowded shorts more squeezable, according to S3 Partners' Ihor Dusaniswky. Dusaniswky created a ranking of the most crowded shorts based on factors like total short dollars at risk, short interest as a true percentage of a company's tradable floa...
Trying to find winners in a bear market is no easy task. Even some of the best blue-chip investments are struggling this year. The S&P 500 has crumbled 20% thus far, and it could get worse before it gets better. One place where investors can find some winners is in the healthc...
Veru ought to find out very soon whether its lead asset, Sabizabulin, has been awarded an Emergency Use Authorization to treat hospitalized COVID patients. The company's share price leapt >$20 when its COVID study data was published, showing a clinically and statistically meaningfu...
Shares of Veru (NASDAQ: VERU) rose by upward of 6% as of 10:23 a.m. ET on Wednesday after it reported in a press release on Tuesday night that it had issued inducement grants to a trio of new employees. In total, the stock options disbursed by the grants allow for the purcha...
Veru (NASDAQ: VERU) , a somewhat under-the-radar coronavirus stock, landed on the radars on many investors at the start of the trading week. An analyst tapped the stock as one of his choice selections, and the market collectively responded by trading the biotech's shares nearly 15% ...
According to the legendary investor Peter Lynch of Fidelity fame, if investing were a baseball game, you'd want to buy stocks in the second inning of a company's lifetime, and sell them in the seventh inning -- or at least sometime before the tail end of the ninth, when everyone in the stad...
Veru 's (NASDAQ: VERU) stock dipped by 5.5% on Friday as of 10:49 a.m. ET after the short-selling group Culper Research published a new report criticizing the company's latest clinical trial results. Culper claims Veru's phase 3 trial data regarding its drug sabizabulin, which w...
Veru Inc. ( NASDAQ: VERU ) fell 6.7% after Culper Research released another short report on the oncology-focused biopharmaceutical company. Culper alleged in the report that at baseline, the VERU ( VERU ) study’s placebo group was "markedly sicker than t...
Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...